https://xl-protein.com/2016/02/01/dnx-biopharmaceuticals-and-xl-protein-enter-into-a-shareholder-agreement-to-develop-and-commercialize-novel-long-acting-biopharma-ceuticals/2016-09-25T17:09:47+02:00https://xl-protein.com/2016/06/14/akari-therapeutics-plc-and-xl-protein-gmbh-sign-license-agreement-to-develop-a-long-acting-version-of-coversin-using-pasylation-technology/2016-09-27T09:17:51+02:00https://xl-protein.com/2015/12/17/xl-protein-and-easton-pharmaceutical-sign-license-agreement-to-develop-biopharmaceuticals-using-pasylation-technology/2016-09-25T17:11:40+02:00https://xl-protein.com/2015/06/30/dnx-and-xl-protein-announce-collaboration-to-develop-novel-long-acting-biopharmaceutical-products/2016-09-26T16:22:43+02:00https://xl-protein.com/2015/02/12/xl-protein-signs-licensing-agreement-with-msd-animal-health-to-develop-biopharmaceuticals-using-its-pasylation-technology/2016-09-26T16:29:04+02:00https://xl-protein.com/2014/10/21/xl-protein-and-yeda-sign-business-collaboration-agreement-to-commercialize-pasylated-interferon-superagonist/2016-09-26T16:32:01+02:00https://xl-protein.com/2013/08/30/xl-protein-announces-publication-of-key-scientific-data-on-its-pasylation-technology/2016-09-26T16:34:20+02:00https://xl-protein.com/2013/04/18/high-yield-with-esetec-and-pasylation-wacker-biotech-and-xl-protein-produce-more-than-four-grams-per-liter-of-fab-antibody-fragment-with-prolonged-plasma-half-life/2016-09-26T16:41:15+02:00https://xl-protein.com/2013/06/26/xl-protein-and-generium-sign-broad-therapeutic-license-and-collaboration-agreement-to-develop-pasylated-therapeutics-for-the-russian-federation/2016-09-26T16:38:44+02:00https://xl-protein.com/2011/01/13/phylogica-collaborates-with-xl-protein-on-inflammation-program/2016-06-16T11:37:09+02:00https://xl-protein.com/2012/10/31/wacker-biotech-and-xl-protein-sign-long-term-cooperation-agreement-to-produce-pasylated-biopharmaceuticals/2016-06-16T11:49:13+02:00https://xl-protein.com/2012/06/11/xl-protein-and-wacker-demonstrate-high-yield-production-of-pasylated-biopharmaceuticals-using-esetec/2016-06-16T12:00:25+02:00https://xl-protein.com/2011/09/23/xl-protein-announces-in-vitro-and-in-vivo-data-for-its-pasylated-hgh/2016-06-16T12:05:35+02:00https://xl-protein.com/2011/03/17/european-patent-granted-for-xl-proteins-pasylation-technology/2016-06-16T12:12:54+02:00https://xl-protein.com/2016/11/07/adalta-xl-protein-announce-collaboration-develop-long-acting-version-lead-fibrosis-drug-candidate-ad-114-using-pasylation-technology/2017-07-26T23:15:50+02:00https://xl-protein.com/2009/09/17/bavarian-patent-alliance-gmbh-biotech-company-xl-protein-gmbh-signed-exclusive-licensing-agreement-promising-invention-technische-universitat-munchen/2017-04-04T11:02:39+02:00https://xl-protein.com/2017/07/26/jazz-pharmaceuticals-xl-protein-gmbh-enter-license-agreement-pasylation-technology-develop-long-acting-asparaginase-product-candidates/2017-07-27T14:13:10+02:00https://xl-protein.com/2017/11/13/adalta-xl-protein-execute-commercial-license-agreement/2017-11-13T14:08:29+01:00https://xl-protein.com/2018/01/07/horizon-pharma-plc-xl-protein-gmbh-entered-collaboration-agreement-potential-next-generation-biologic-uncontrolled-gout-using-pasylation-technology/2018-01-10T03:13:50+01:00https://xl-protein.com/2018/12/18/ajinomoto-xl-protein-forge-strategic-alliance-develop-pasylated-therapeutics-applying-corynex-platform/2018-12-18T18:11:25+01:00https://xl-protein.com/2020/02/18/dnx-biopharmaceuticals-announces-collaboration-lung-cancer-initiative-johnson-johnson/2020-02-18T22:57:59+01:00https://xl-protein.com/2020/01/27/akari-therapeutics-announces-preclinical-ophthalmic-data-showing-nomacopan-reduces-vascular-endothelial-growth-factor-vegf-retinal-inflammation-supporting-nomacopan-potential-treatment/2020-02-18T23:03:13+01:00https://xl-protein.com/2019/04/26/akari-therapeutics-announces-expanded-ophthalmology-program-based-positive-emerging-data-ltb4-c5-dual-action-surface-back-eye-diseases/2020-02-19T13:11:52+01:00https://xl-protein.com/2020/02/25/xl-protein-dnx-biopharmaceuticals-announce-collaboration-develop-novel-inflammasome-directed-therapeutics-using-pasylation-technology/2020-02-25T15:59:48+01:00https://xl-protein.com/2020/10/15/xl-protein-and-antlia-bioscience-announce-collaboration-to-develop-long-acting-peptide-therapy-of-chronic-heart-failure-using-pasylation-technology/2020-10-16T10:48:25+02:00https://xl-protein.com/2021/07/12/xl-protein-announces-the-avi-pas-mab-platform-to-boost-the-preclinical-and-clinical-development-of-therapies-using-its-pasylation-technology/2021-07-12T13:22:12+02:00https://xl-protein.com/2021/02/25/akari-therapeutics-presents-new-preclinical-data-highlighting-potential-of-long-acting-pasylated-nomacopan-to-treat-retinal-diseases-including-age-related-macular-degeneration-amd-and-uveitis/2021-09-10T15:01:56+02:00https://xl-protein.com/2021/10/26/rentschler-biopharma-and-xl-protein-demonstrate-efficient-production-of-a-hyperactive-pasylated-dnase-i-with-extended-half-life/2021-10-26T10:46:19+02:00https://xl-protein.com/2022/07/29/akari-therapeutics-announces-positive-results-from-recent-pre-clinical-studies-of-investigational-pasylated-nomacopan-that-support-the-potential-to-advance-research-toward-ind-impd-for-clinical/2022-07-29T20:58:10+02:00https://xl-protein.com/2022/09/28/bavarian-research-foundation-supports-the-development-of-an-immunosuppressive-pasylated-antibody-fragment-to-support-cardiac-xenotransplantation/2022-09-28T15:54:56+02:00https://xl-protein.com/2023/02/15/akari-therapeutics-announces-pre-clinical-development-progress-toward-potential-ind-on-long-acting-pas-nomacopan-for-geographic-atrophy-ga/2023-02-21T10:07:28+01:00https://xl-protein.com/2025/06/10/xl-protein-grants-worldwide-license-to-grifols-to-develop-a-biopharmaceutical-using-pasylation-technology/2025-06-10T11:20:12+02:00